Halaman 9 - MRI satu daerah Dokter Terbaik di Turquia - TOP-328 dokter

Dr. Idris Sertbas is a skilled neurosurgeon with experience in both adult and pediatric brain and spine surgeries. He performs complex procedures such as brain and cerebellum tumor surgeries. He also treats children with conditions like hydrocephalus, tethered cord, and craniosynostosis. Dr. Sertbas is experienced in advanced spine surgeries, including stabilization for disc herniation, vertebroplasty, and kyphosis surgery.

He is trained in neuromodulation surgeries, such as deep brain stimulation for Parkinson’s disease, epilepsy stimulation, and spinal cord stimulation for chronic pain. He also performs procedures for trigeminal neuralgia, hemifacial spasm, and baclofen pump implantation for severe spasticity.

Dr. Sertbas graduated from Sivas Cumhuriyet University and completed his neurosurgery training at Ankara Training and Research Hospital. He has worked at Bartın State Hospital and Istanbul Yeni Yüzyıl University. He now practices at the Neurosurgery Clinic of Liv Vadistanbul Hospital.

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Areas of Interests

• Demyelinating Diseases and MS
• Peripheral Neuropathy and Motor Neuron Disease (ALS)
• Neuromuscular Junction Diseases (MG)

Education 

• M.Sc. Faculty of Medicine, Ondokuz Mayıs University  1990
• Specialization in Medicine  Neurology,  Ankara Training and Research Hospital 1997
• Minor Specialization  Clinical Neurophysiology, Medical Specialization Board 2011

Experience

• Doctor MoH Kastamonu and Samsun Health Center No. 7 1990-1992
• Dr. Res.Assist. Ankara Training and Research Hospital Neurology Clinic 1992-1997
• Assoc. Dr. Abant İzzet Baysal University Düzce Faculty of Medicine 1999-2006
• Assoc.Dr. Duzce University Faculty of Medicine 2007-2011
• Prof.Dr  Duzce University Faculty of Medicine  2011-

Education & Expertise

1995 to 2001 | Ege University Faculty of Medicine – Medical Education

2001 to 2006 | Dokuz Eylül University Faculty of Medicine – Internal Medicine Specialization

2008 to 2011 | Göztepe Training and Research Hospital – Gastroenterology Subspecialty

2014 | Ümraniye Training and Research Hospital – Associate Professor of Gastroenterology

2021 | University of Health Sciences – Professor

Professional Experience

2007 | Nusaybin State Hospital – Internal Medicine Specialist (Civil Service Obligation)

2011 to 2014 | Ümraniye Training and Research Hospital – Gastroenterology Specialist

2014 to 2017 | Ümraniye Training and Research Hospital – Associate Professor of Gastroenterology

2017 to 2021 | Health Sciences University – Associate Professor of Gastroenterology

2015 to 2021 | Ümraniye Training and Research Hospital Gastroenterology Clinic – Clinic Chief

2021 to 2022 | University of Health Sciences – Professor of Internal Medicine and Gastroenterology

2015 to 2022 | Genomic Laboratory (GLAB) Coordinator, Istanbul Provincial Health Directorate

2014 to 2021 | Northern Clinics of Istanbul Journal (indexed in WoS and PubMed) – Founding Editor

2021 to Present | Turkish Liver Research Association – Board Member

2022 to Present | Hepatology Bulletin Journal – Editor

2019 to Present | Hepatology Forum Magazine – Editor

2016 to Present | World Journal of Hepatology – Editor

International Experience

1999 | Trainee Doctor, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK

2000 | Trainee Doctor, Cardiology Unit, North Manchester General Hospital, Manchester, UK

2005 | Assistant Doctor, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK

Professional Memberships

Turkish Gastroenterology Association

Turkish Liver Research Association

EASL – European Association for the Study of Liver

APASL – Asian Pacific Association for the Study of Liver

AAAS – American Association for the Advancement of Science

Awards & Recognitions

2013 | Liver Fibrosis Pathways in Chronic Hepatitis B: A Comparative Proteomic Study – Gilead Fellowship Award

2014 | Liver Fibrosis Pathways in Chronic Hepatitis B: A Comparative Proteomic Study – Viral Hepatitis Fight Association Project Support Award

2014 | The Relationship between Spontaneous Seroconversion and Toll-Like Receptor Gene Polymorphism in Hepatitis B Infection – Turkish Gastroenterology Association, Best Poster Second Prize

2015 | Research on Damage Pathways in Liver Tissue in Chronic Hepatitis B: A Comparative Proteomic Study – Turkish Gastroenterology Association, Best Oral Presentation Third Prize

2016 | Investigations of the EGF and Its Receptor EGFR Gene Variants in Ulcerative Colitis – XV Euroasian Congress of Gastroenterology and Surgery, Best Oral Presentation Third Prize

Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

Professional Experience

• 1999-2000: Şırnak Military Hospital, Military Service
• 2001-2007: Süreyyapaşa Chest, Heart, and Vascular Diseases Hospital, Cardiovascular Surgery Clinic
  • Contributed to the establishment of the Cardiovascular Surgery Clinic
  • 2005: Awarded the title of Associate Professor in Cardiovascular Surgery
• 2007-2009: Kartal Koşuyolu High Specialization Training and Research Hospital
• 2009-2011: Kartal Koşuyolu High Specialization Training and Research Hospital, Cardiovascular Surgery Clinic, Assistant Chief
• 2011-2017: Kartal Koşuyolu High Specialization Training and Research Hospital, Cardiovascular Surgery Clinic, Instructor
• 2016-2017: Kartal Koşuyolu High Specialization Training and Research Hospital, Cardiovascular Surgery Clinic, Education Officer
• 2017-2024: Bezmialem Vakıf University, Faculty of Medicine, Professor
  • Head of Cardiovascular Surgery Department, Bezmialem Vakıf University, Faculty of Medicine
• Since July 2024: Medipol Acıbadem District l Hospital, Cardiovascular Surgeon

Education

• 1986-1989, Bursa High School, Bursa, Turkey
• 1989-1995, Istanbul University, Istanbul School of Medicine, Turkey
• 1999-2003, (Residency) Kadir Has University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey
• 2015, (Associate Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Experience

• 1995-1999, Şişli Florence Nightingale Hospital, Istanbul, Cardiology Department
• 2003, Gayrettepe Florence Nightingale Hospital, Istanbul, Department of Radiation Oncology
• 2015, (Associate Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Education

• (2004 – 2011), Faculty of Medicine/ Inonu University/ Malatya, Turkiye
• (2011 – 2015), Department of Radiology/ Bagcilar Training and Research Hospital/ Istanbul, Turkiye

Career

• (2016 – 2020), Diagnostic and Interventional Radiologist/ Mus State Hospital/ Mus,Turkiye
• (2020 – 2022), Assistant Professor of Diagnostic and Interventional Radiology/ Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2023 – 2024), Associate Professor of Diagnostic and Interventional Radiology /Sakarya University Training and Research Hospital/ Sakarya, Turkiye
• (2024 - Present), Associate Professor of Diagnostic and Interventional Radiology /Medipol University Hospital/ Istanbul, Turkiye

Experience

2018

Private Istanbul Medipol Hospital

2018

Medipol University Camlica Hospital

2018

Medipol Camlica Hospital

2013 - 2018

Medipol Mega University Hospital

2011 - 2013

Yuzuncu Yil University Hospital

2010 - 2011

Gulhane Military Medical Academy

2010 - 2013

Yuzuncu Yil University Hospital

2010 - 2011

Gulhane Military Medical Academy

2010 - 2011

Gulhane Military Medical Academy

2010 - 2013

Yuzuncu Yil University Faculty of Medicine

2009

University of Toronto SickKids Hospital

2004 - 2008

Private Van-Etfal Pediatric Diseases

1999 - 2004

Yuzuncu Yil University Hospital

Education

2010

Yuzuncu Yil University, Pediatric Nephrology

2004

Yuzuncu Yil University, Pediatrics

1998

Ege University, Faculty of Medicine

Experience

2019 - 2022 Medipol University

2010 Private Nisa Hospital

2008 - 2010 Kaman State Hospital

Education

2008

Istanbul University Cerrahpaşa Faculty of Medicine, Obstetrics and Gynecology

2002

Istanbul University, Istanbul Faculty of Medicine

Dr. Ali Osman Mucuoglu is a neurosurgeon. He completed his neurosurgery residency at Dokuz Eylül University from 2013 to 2019 after graduating from Eskişehir Osmangazi University in 2012 (2005–2012). He worked at Dokuz Eylül University and Muş State Hospital from 2019 to 2021. He has practiced at Atlas University Hospital since 2021.

He has five publications. These include a case report in the International Journal of Surgery Case Reports that has been cited seven times. He also reported on 3D printer‑assisted transsphenoidal hypophysectomy and on emergency minimally invasive intracerebral hemorrhage (ICH) surgery. He delivered an oral presentation at the 33rd Turkish Neurosurgical Society Congress in 2019.

He is a member of the Turkish Neurosurgical Society, the European Association of Neurosurgical Societies, and the Istanbul Chamber of Medicine. His advanced training includes spinal surgery courses in 2016 and 2017, the European Training Course on Head Injury and Functional Neurosurgery in 2017, and Surgical Neuroanatomy in 2017. He also holds an animal experimentation certificate from 2016.

Dr. Hayrettin Kesmezacar is an orthopaedic surgeon at Gayrettepe Florence Nightingale Hospital in Istanbul. He joined the hospital in 2013 and holds a current appointment from 2024. His clinical focus includes shoulder and elbow surgery, shoulder instability, rotator cuff tears, and orthopaedic trauma.

He became Professor at Bilim University Medical Faculty in 2011. He was appointed Associate Professor at Istanbul University-Cerrahpaşa in 2006. His training includes residency and fellowship at Cerrahpaşa in 1997 and 2000. He completed visiting fellowships at Cornell HSS in 2004 and Western Ontario/LHSC in 2009. He holds a CRA certificate from Oxford College (2024). As of 2024, he serves as a CRA at Mount Sinai Hospital ICU Research (iCORE).

He has peer-reviewed publications in J Shoulder Elbow Surg, Acta Orthop Traumatol Turc, Arthroscopy, and others. His work includes a 22.4-year follow-up study on displaced supracondylar humerus fractures. He also reported 6-year outcomes for hallux valgus.

EDUCATION:

• Turhan and Mediha Tansel Primary School (1979–1984)
• Kültür College (1984–1988)
• Semiha Şakir High School (1988–1991)
• Marmara University Faculty of Medicine (1991–1997)
• Marmara University Faculty of Medicine, Neurosurgery Department, Specialist Training (1997–2002)
• Title of Associate Professor in Neurosurgery (May 31, 2021)

ADDITIONAL TRAINING:

• "Visiting Physician," University of Southern California, Department of Neurosurgery (1998)
• "Microsurgery Training," GATA (Gülhane Military Medical Academy), Ankara Education and Research Hospital (2003)

PROFESSIONAL EXPERIENCE:

• Gülhane Military Medical Academy Haydarpaşa Training and Research Hospital (2002–2003)
• Dr. Lütfi Kırdar Kartal Training and Research Hospital (2003–2005)
• Private Avicenna Ataşehir Hospital (2005–2012)
• Private 29 Mayıs Hospital (2012–2013)
• Maltepe State Hospital (2013–2018)
• Kartal Dr. Lütfi Kırdar City Hospital (2018–2020)
• Private Academic Hospital (2020–2022)
• Hisar Intercontinental Hospital (2022–2024)
• Private Medipol Acıbadem Regional Hospital (2024–Present)

ADMINISTRATIVE AND ACADEMIC ROLES:

• Board Member, Neurosurgical Society (2006–2009)
• Head of the Emergency Department, Maltepe State Hospital (2014–2016)
• Deputy Chief Physician, Private Academic Hospital (2020–2021)
• Advisory Board Member, Beykent University Faculty of Medicine (2018–2024)
• Faculty Member, Galata University Faculty of Health Sciences (2022–2024)
• Director, Continuous Education Center, Galata University (2022–2024)

Personal Information

Name Surname: İbrahim COŞKUNER

Birthplace - Year: 1964

Academic Title: Op. Dr.

Foreign Language: English

Education

Karadeniz University Faculty of Medicine

SB Ankara Hospital

Work Experience

Bursa City Hospital 2020

Artvin State Hospital 2005

Osteoarthritis Treatment; Intra-articular Botox Application

Treatment of Nonunion Fractures with new generation Composite Implants

Use of Composite Implants in early Fracture Healing

Joint Replacement in Hip and Knee Arthritis; Replacement of Joint with Prosthesis - Quality Metal Implants

Stem Cell Applications in Developmental Disorders

Knee Ligament Injury Repair Reconstructive Interventions

Spine Curvature Treatment Surgical Intervention

Ilizarov System Applications Surgical Treatment of Open Fractures, Correction of Deformities

Trauma to the bone structures

Knee Surgery

Structural Bone Disorders

Hand Surgery Athlete Traumatology

Pediatric Surgery

Intra-Articular Injections

PRP Injection

Anterior Cruciate Ligament Surgery

EDUCATION:

2009

Ankara Etlik Maternity Hospital and Gynecology Education and Research Hospital, Gynecology and Obstetrics

2003

Ankara University, Faculty of Medicine

EXPERIENCE:

2019 - to present

Medipol University Pendik Hospital

2009 - 2019

Yakacık Maternity and Child Diseases Hospital

PUBLICATIONS:

Articles Published in Journals Indexed in SCI, SSCI and AHCI

Isoflavones obtained from red clover improve both dyslipidemia and menopausal symptoms in menopausal women: a prospective randomized placebo-controlled trial

YİĞİT E., ÜNSAL S.

Climacteric , 2024 (SCI-Expanded)

EDUCATION:

2000 - SSK Okmeydanı Training and Research Hospital, .

1996 - Istanbul University, Istanbul Faculty of Medicine

EXPERIENCE:

2019 - Istanbul Medipol University Pendik Hospital

2017 - 2019 - Private Adatıp Kurtköy Hospital

2005 - 2017 - Private Avicenna Umut Hospital

2003 - 2005 - SSK Yalova Regional Hospital

2002 - 2003 - Kayseri Military Hospital

Dr. Omer Burcak Binicier is a gastroenterology specialist with strong medical training. He earned his medical degree at Ege University. He completed his internal medicine and gastroenterology specialization at Dokuz Eylül University Faculty of Medicine. Dr. Binicier has over ten years of clinical experience. He has held key positions at SBÜ Tepecik Training and Research Hospital and İzmir Bayraklı City Hospital. He also gained international experience at Korea University.

Dr. Binicier diagnoses and treats a wide range of gastrointestinal diseases. His expertise includes early colon and stomach cancers, inflammatory bowel diseases, liver and pancreatic disorders, and digestive system cancers. He uses advanced endoscopic techniques such as EMR, ESD, ERCP, and endoscopic ultrasound. He is also skilled in minimally invasive obesity treatments. His clinical skills are built on years of hands-on work in top medical centers.

Dr. Burcin Kececi is a specialist in orthopedics and traumatology. He focuses on pediatric orthopedics, bone metastases, bone and soft tissue tumors, and orthopedic oncology. He performs advanced surgeries on the knee, hip, ankle, elbow, hand, and shoulder. His skills also include prosthesis replacements, limb lengthening, tendon transfers, and trauma surgery.

He received additional training in France in knee, hip, and sports injuries. He also trained in minimally invasive hip surgery. Dr. Kececi has worked at Ege University and İzmir Private Hospital. He currently practices at Medical Point İzmir Hospital. He is a member of national and international orthopedic and oncology societies, including ISOLS, SICOT, and EMSOS. He has also served on the board of TOTBİD.